{
  "id": 1076,
  "documents": {
    "1076": {
      "createdDate": "2024-12-16T19:42:31.523Z",
      "original": "<!DOCTYPE html ><html><body><div>H-0077.1</div><hr style=\"margin-left:1.25in;margin-right:1.25in;height:1px;color:#333;\" /><div style=\"font-weight:bold;text-align:center;\">HOUSE BILL 1076</div><hr style=\"margin-left:1.25in;margin-right:1.25in;height:1px;color:#333;\" /><table style=\"width:622px;margin-top:0.1in;\"><tr><td><div style=\"font-weight:bold;\">State of Washington</div></td><td><div style=\"font-weight:bold;\">69th Legislature</div></td><td><div style=\"font-weight:bold;\">2025 Regular Session</div></td></tr></table><div style=\"margin-top:0.1in;\"><span style=\"font-weight:bold;margin-right:0.25in;\">By</span><!-- field: Sponsors -->Representatives Walen, Barnard, Reed, Rule, Ryu, Parshley, Leavitt, and Obras<!-- field: --></div><div style=\"margin-top:0.1in;\"><span style=\"margin-right:0.25in;\">Prefiled 12/16/24.</span><span style=\"margin-right:0.25in;\">Read first time 01/13/25.</span><span style=\"margin-right:0.25in;\">Referred to Committee on Health Care &amp; Wellness.</span></div><div style=\"text-indent:0.5in;margin-top:0.5in;\"><!-- field: CaptionsTitles -->AN ACT Relating to the health technology assessment program; and amending RCW  <a href='http://app.leg.wa.gov/RCW/default.aspx?cite=70.14.100'>70.14.100</a> and  <a href='http://app.leg.wa.gov/RCW/default.aspx?cite=70.14.110'>70.14.110</a>.<!-- field: --></div><div style=\"margin-top:0.25in;margin-bottom:0.25in;\">BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF WASHINGTON:</div><div style=\"margin-top:0.25in;text-indent:0.5in;\"><!-- field: BeginningSection --><span style=\"font-weight:bold;padding-right:0.1in;\">Sec. 1.  </span>RCW  <a href='http://app.leg.wa.gov/RCW/default.aspx?cite=70.14.100'>70.14.100</a> and 2006 c 307 s 3 are each amended to read as follows:<!-- field: --></div><div style=\"text-indent:0.5in;\"><!-- field: Text -->(1) The administrator, in consultation with participating agencies and the committee, shall select the health technologies to be reviewed by the committee under RCW  <a href='http://app.leg.wa.gov/RCW/default.aspx?cite=70.14.110'>70.14.110</a>. Up to six may be selected for review in the first year after June 7, 2006, and up to eight may be selected in the second year after June 7, 2006. In making the selection, priority shall be given to any technology ((<span style=\"text-decoration:line-through;\">for</span>))<span style=\"text-decoration:underline;\">:</span></div><div style=\"text-indent:0.5in;\"><span style=\"text-decoration:underline;\">(a) For which patient access is established or recommended for a patient population under the federal medicare program, including local coverage determinations or national coverage determinations, or in nationally recognized expert treatment guidelines, including guidelines developed by the national comprehensive cancer network, specialty physician organizations, or patient advocacy organizations; or</span></div><div style=\"text-indent:0.5in;\"><span style=\"text-decoration:underline;\">(b) For</span> which:</div><div style=\"text-indent:0.5in;\">((<span style=\"text-decoration:line-through;\">(a)</span>))<span style=\"text-decoration:underline;\">(i)</span> There are concerns about its safety, efficacy, or cost-effectiveness, especially relative to existing alternatives, or significant variations in its use;</div><div style=\"text-indent:0.5in;\">((<span style=\"text-decoration:line-through;\">(b)</span>))<span style=\"text-decoration:underline;\">(ii)</span> Actual or expected state expenditures are high, due to demand for the technology, its cost, or both; and</div><div style=\"text-indent:0.5in;\">((<span style=\"text-decoration:line-through;\">(c)</span>))<span style=\"text-decoration:underline;\">(iii)</span> There is adequate evidence available to conduct the complete review.</div><div style=\"text-indent:0.5in;\">(2) A health technology for which the committee has made a determination under RCW  <a href='http://app.leg.wa.gov/RCW/default.aspx?cite=70.14.110'>70.14.110</a> shall be considered for rereview at least once every eighteen months, beginning the date the determination is made. The administrator, in consultation with participating agencies and the committee, shall select the technology for rereview if he or she decides that evidence has since become available that could change a previous determination. Upon rereview, consideration shall be given ((<span style=\"text-decoration:line-through;\">only</span>)) to evidence made available since the <span style=\"text-decoration:underline;\">committee's</span> previous determination <span style=\"text-decoration:underline;\">evaluated in combination and within the context of the clinical evidence the committee considered previously</span>.</div><div style=\"text-indent:0.5in;\">(3) Pursuant to a petition submitted by an interested party, the health technology clinical committee may select health technologies for review that have not otherwise been selected by the administrator under subsection (1) or (2) of this section.</div><div style=\"text-indent:0.5in;\">(4) Upon the selection of a health technology for review, the administrator shall contract for a systematic evidence-based assessment of the technology's safety, efficacy, and cost-effectiveness. The contract shall:</div><div style=\"text-indent:0.5in;\">(a) Be with an evidence-based practice center designated as such by the federal agency for health care research and quality, or other appropriate entity;</div><div style=\"text-indent:0.5in;\">(b) Require the assessment be initiated no sooner than thirty days after notice of the selection of the health technology for review is posted on the internet under RCW  <a href='http://app.leg.wa.gov/RCW/default.aspx?cite=70.14.130'>70.14.130</a>;</div><div style=\"text-indent:0.5in;\">(c) Require, in addition to other information considered as part of the assessment, consideration of: (i) Safety, health outcome, and cost data submitted by a participating agency; and (ii) evidence submitted by any interested party; and</div><div style=\"text-indent:0.5in;\">(d) Require the assessment to: (i) Give the greatest weight to the evidence determined, based on objective indicators, to be the most valid and reliable, considering the nature and source of the evidence, the empirical characteristic of the studies or trials upon which the evidence is based, and the consistency of the outcome with comparable studies; and (ii) take into account any unique impacts of the technology on specific populations based upon factors such as sex, age, ethnicity, race, or disability.</div><div style=\"text-indent:0.5in;\"><span style=\"text-decoration:underline;\">(5) In the case of life-threatening or rare diseases, the committee shall:</span></div><div style=\"text-indent:0.5in;\"><span style=\"text-decoration:underline;\">(a) Evaluate all applicable clinical trials regarding the technology published in the peer-reviewed clinical literature including, but not limited to, randomized controlled trials; and</span></div><div style=\"text-indent:0.5in;\"><span style=\"text-decoration:underline;\">(b) If applicable, take into account information submitted by clinical experts indicating that performing a randomized controlled trial or other specific trial design would be unethical, impractical, or impossible with respect to the given technology within a specific patient population.</span><!-- field: --></div><!-- field: --><div style=\"margin-top:0.25in;text-indent:0.5in;\"><!-- field: BeginningSection --><span style=\"font-weight:bold;padding-right:0.1in;\">Sec. 2.  </span>RCW  <a href='http://app.leg.wa.gov/RCW/default.aspx?cite=70.14.110'>70.14.110</a> and 2006 c 307 s 4 are each amended to read as follows:<!-- field: --></div><div style=\"text-indent:0.5in;\"><!-- field: Text -->(1) The committee shall determine, for each health technology selected for review under RCW  <a href='http://app.leg.wa.gov/RCW/default.aspx?cite=70.14.100'>70.14.100</a>: (a) The conditions, if any, under which the health technology will be included as a covered benefit in health care programs of participating agencies; and (b) if covered, the criteria which the participating agency administering the program must use to decide whether the technology is medically necessary, or proper and necessary treatment.</div><div style=\"text-indent:0.5in;\">(2) In making a determination under subsection (1) of this section, the committee:</div><div style=\"text-indent:0.5in;\">(a) Shall consider, in an open and transparent process, evidence regarding the safety, efficacy, and cost-effectiveness of the technology as set forth in the systematic assessment conducted under RCW  <a href='http://app.leg.wa.gov/RCW/default.aspx?cite=70.14.100'>70.14.100</a>(4);</div><div style=\"text-indent:0.5in;\">(b) Shall provide an opportunity for public comment; and</div><div style=\"text-indent:0.5in;\">(c) May establish ad hoc temporary advisory groups if specialized expertise is needed to review a particular health technology or group of health technologies, or to seek input from enrollees or clients of state purchased health care programs. Advisory group members are immune from civil liability for any official act performed in good faith as a member of the group. As a condition of appointment, each person shall agree to the terms and conditions imposed by the administrator regarding conflicts of interest.</div><div style=\"text-indent:0.5in;\">(3) Determinations of the committee under subsection (1) of this section shall be consistent with decisions made under the federal medicare program and in expert treatment guidelines, including those from specialty physician organizations and patient advocacy organizations, unless the committee concludes, based on its review of the systematic assessment, that substantial evidence regarding the safety, efficacy, and cost-effectiveness of the technology supports a contrary determination.</div><div style=\"text-indent:0.5in;\"><span style=\"text-decoration:underline;\">(4) The health care authority shall publish receipt of submissions for new technology assessment and rereview assessments on the authority's website within seven days of receipt. The committee shall review, complete its determination, and communicate its decision for a new technology assessment or rereview assessment to the submitting party within 180 days of the initial date of submission. In the case of an adverse determination, the committee shall provide the submitting party with a written substantive explanation of the rationale for the adverse determination within 180 days of the initial date of submission.</span><!-- field: --></div><!-- field: --><div style=\"margin-top:0.1in;font-weight:bold;text-align:center;\">--- END ---</div></body></html>",
      "summary": "<h3>Purpose</h3>\n<p>The purpose of House Bill 1076 is to amend the health technology assessment program in Washington State. The bill seeks to improve the process of reviewing health technologies for safety, efficacy, and cost-effectiveness. Key changes include a more structured selection process for health technologies, the introduction of a reevaluation schedule, and clearer guidelines for public participation in decision-making. These updates aim to ensure that assessments are comprehensive, transparent, and based on the most current evidence.</p>\n<h3>Key Provisions</h3>\n<h4>Selection of Health Technologies</h4>\n<ul>\n<li>The administrator will select up to six health technologies for review in the first year and up to eight in the second year following a specified date, prioritizing technologies:<ul>\n<li>Approved for patient populations under federal Medicare or recognized expert guidelines.</li>\n<li>For which safety, efficacy, or cost-effectiveness is queried.</li>\n<li>Assigned significant state expenditure due to demand or cost.</li>\n<li>Supported by sufficient evidence for a complete review.</li></ul></li>\n</ul>\n<h4>Reevaluation Process</h4>\n<ul>\n<li>Technologies assessed by the committee will be eligible for reevaluation at least every eighteen months if new evidence could change prior conclusions.</li>\n<li>Only new evidence and context from previous reviews will be considered during reevaluations.</li>\n</ul>\n<h4>Public Involvement</h4>\n<ul>\n<li>Interested parties can petition for the review of technologies not initially selected by the administrator.</li>\n<li>The committee will ensure the assessment process is open to public comments.</li>\n</ul>\n<h4>Systematic Assessment Contracts</h4>\n<ul>\n<li>Upon selecting a technology for review, the administrator will contract a designated evidence-based practice center to conduct a thorough assessment, which must account for:<ul>\n<li>Safety, health outcomes, and cost data from agencies and interested parties.</li>\n<li>The reliability and validity of the evidence provided.</li>\n<li>Unique impacts on specific populations based on demographics.</li></ul></li>\n</ul>\n<h4>Special Considerations for Life-Threatening Conditions</h4>\n<ul>\n<li>For technologies related to life-threatening or rare diseases, the committee will evaluate all relevant clinical trials published in peer-reviewed literature.</li>\n<li>Will consider circumstances where traditional trials may be unethical or impractical.</li>\n</ul>\n<h4>Determination of Coverage</h4>\n<ul>\n<li>The committee will determine the conditions under which a technology may be covered in health care programs and the criteria for establishing medical necessity.</li>\n<li>The process will be open and transparent, involving public comments and possibly forming temporary advisory groups for specialized insight.</li>\n</ul>\n<h4>Communication of Assessments</h4>\n<ul>\n<li>The health care authority must publish new submissions for technology assessment on its website within seven days and must communicate decisions and rationales to submitting parties within 180 days.</li>\n</ul>"
    },
    "1076-S": {
      "createdDate": "2025-02-03T16:26:22.883Z",
      "original": "<!DOCTYPE html ><html><body><div>H-1115.1</div><hr style=\"margin-left:1.25in;margin-right:1.25in;height:1px;color:#333;\" /><div style=\"font-weight:bold;text-align:center;\">SUBSTITUTE HOUSE BILL 1076</div><hr style=\"margin-left:1.25in;margin-right:1.25in;height:1px;color:#333;\" /><table style=\"width:622px;margin-top:0.1in;\"><tr><td><div style=\"font-weight:bold;\">State of Washington</div></td><td><div style=\"font-weight:bold;\">69th Legislature</div></td><td><div style=\"font-weight:bold;\">2025 Regular Session</div></td></tr></table><div style=\"margin-top:0.1in;\"><span style=\"font-weight:bold;margin-right:0.25in;\">By</span><!-- field: Sponsors -->House Health Care &amp; Wellness (originally sponsored by Representatives Walen, Barnard, Reed, Rule, Ryu, Parshley, Leavitt, and Obras)<!-- field: --></div><div style=\"margin-top:0.1in;\"><span style=\"margin-right:0.25in;\">READ FIRST TIME 02/04/25.</span></div><div style=\"text-indent:0.5in;margin-top:0.5in;\"><!-- field: CaptionsTitles -->AN ACT Relating to the health technology assessment program; and amending RCW  <a href='http://app.leg.wa.gov/RCW/default.aspx?cite=70.14.100'>70.14.100</a> and  <a href='http://app.leg.wa.gov/RCW/default.aspx?cite=70.14.110'>70.14.110</a>.<!-- field: --></div><div style=\"margin-top:0.25in;margin-bottom:0.25in;\">BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF WASHINGTON:</div><div style=\"margin-top:0.25in;text-indent:0.5in;\"><!-- field: BeginningSection --><span style=\"font-weight:bold;padding-right:0.1in;\">Sec. 1.  </span>RCW  <a href='http://app.leg.wa.gov/RCW/default.aspx?cite=70.14.100'>70.14.100</a> and 2006 c 307 s 3 are each amended to read as follows:<!-- field: --></div><div style=\"text-indent:0.5in;\"><!-- field: Text -->(1) The administrator, in consultation with participating agencies and the committee, shall select the health technologies to be reviewed by the committee under RCW  <a href='http://app.leg.wa.gov/RCW/default.aspx?cite=70.14.110'>70.14.110</a>. Up to six may be selected for review in the first year after June 7, 2006, and up to eight may be selected in the second year after June 7, 2006. In making the selection, priority shall be given to any technology ((<span style=\"text-decoration:line-through;\">for</span>))<span style=\"text-decoration:underline;\">:</span></div><div style=\"text-indent:0.5in;\"><span style=\"text-decoration:underline;\">(a) For which patient access is established or recommended for a patient population under the federal medicare program, including local coverage determinations or national coverage determinations, or in nationally recognized expert treatment guidelines, including guidelines developed by specialty physician organizations or patient advocacy organizations; and</span></div><div style=\"text-indent:0.5in;\"><span style=\"text-decoration:underline;\">(b) For</span> which:</div><div style=\"text-indent:0.5in;\">((<span style=\"text-decoration:line-through;\">(a)</span>))<span style=\"text-decoration:underline;\">(i)</span> There are concerns about its safety, efficacy, or cost-effectiveness, especially relative to existing alternatives, or significant variations in its use;</div><div style=\"text-indent:0.5in;\">((<span style=\"text-decoration:line-through;\">(b)</span>))<span style=\"text-decoration:underline;\">(ii)</span> Actual or expected state expenditures are high, due to demand for the technology, its cost, or both; and</div><div style=\"text-indent:0.5in;\">((<span style=\"text-decoration:line-through;\">(c)</span>))<span style=\"text-decoration:underline;\">(iii)</span> There is adequate evidence available to conduct the complete review.</div><div style=\"text-indent:0.5in;\">(2) A health technology for which the committee has made a determination under RCW  <a href='http://app.leg.wa.gov/RCW/default.aspx?cite=70.14.110'>70.14.110</a> shall be considered for rereview at least once every eighteen months, beginning the date the determination is made. The administrator, in consultation with participating agencies and the committee, shall select the technology for rereview if he or she decides that evidence has since become available that could change a previous determination. Upon rereview, consideration shall be given ((<span style=\"text-decoration:line-through;\">only</span>)) to evidence made available since the <span style=\"text-decoration:underline;\">committee's</span> previous determination <span style=\"text-decoration:underline;\">evaluated in combination and within the context of the clinical evidence the committee considered previously</span>.</div><div style=\"text-indent:0.5in;\">(3) Pursuant to a petition submitted by an interested party, the health technology clinical committee may select health technologies for review that have not otherwise been selected by the administrator under subsection (1) or (2) of this section.</div><div style=\"text-indent:0.5in;\">(4) Upon the selection of a health technology for review, the administrator shall contract for a systematic evidence-based assessment of the technology's safety, efficacy, and cost-effectiveness. The contract shall:</div><div style=\"text-indent:0.5in;\">(a) Be with an evidence-based practice center designated as such by the federal agency for health care research and quality, or other appropriate entity;</div><div style=\"text-indent:0.5in;\">(b) Require the assessment be initiated no sooner than thirty days after notice of the selection of the health technology for review is posted on the internet under RCW  <a href='http://app.leg.wa.gov/RCW/default.aspx?cite=70.14.130'>70.14.130</a>;</div><div style=\"text-indent:0.5in;\">(c) Require, in addition to other information considered as part of the assessment, consideration of: (i) Safety, health outcome, and cost data submitted by a participating agency; and (ii) evidence submitted by any interested party; and</div><div style=\"text-indent:0.5in;\">(d) Require the assessment to: (i) Give the greatest weight to the evidence determined, based on objective indicators, to be the most valid and reliable, considering the nature and source of the evidence, the empirical characteristic of the studies or trials upon which the evidence is based, and the consistency of the outcome with comparable studies; and (ii) take into account any unique impacts of the technology on specific populations based upon factors such as sex, age, ethnicity, race, or disability.</div><div style=\"text-indent:0.5in;\"><span style=\"text-decoration:underline;\">(5) In the case of life-threatening or rare diseases, the committee shall:</span></div><div style=\"text-indent:0.5in;\"><span style=\"text-decoration:underline;\">(a) Evaluate all applicable clinical trials regarding the technology published in the peer-reviewed clinical literature including, but not limited to, randomized controlled trials; and</span></div><div style=\"text-indent:0.5in;\"><span style=\"text-decoration:underline;\">(b) If applicable, take into account information submitted by clinical experts indicating that performing a randomized controlled trial or other specific trial design would be unethical, impractical, or impossible with respect to the given technology within a specific patient population.</span><!-- field: --></div><!-- field: --><div style=\"margin-top:0.25in;text-indent:0.5in;\"><!-- field: BeginningSection --><span style=\"font-weight:bold;padding-right:0.1in;\">Sec. 2.  </span>RCW  <a href='http://app.leg.wa.gov/RCW/default.aspx?cite=70.14.110'>70.14.110</a> and 2006 c 307 s 4 are each amended to read as follows:<!-- field: --></div><div style=\"text-indent:0.5in;\"><!-- field: Text -->(1) The committee shall determine, for each health technology selected for review under RCW  <a href='http://app.leg.wa.gov/RCW/default.aspx?cite=70.14.100'>70.14.100</a>: (a) The conditions, if any, under which the health technology will be included as a covered benefit in health care programs of participating agencies; and (b) if covered, the criteria which the participating agency administering the program must use to decide whether the technology is medically necessary, or proper and necessary treatment.</div><div style=\"text-indent:0.5in;\">(2) In making a determination under subsection (1) of this section, the committee:</div><div style=\"text-indent:0.5in;\">(a) Shall consider, in an open and transparent process, evidence regarding the safety, efficacy, and cost-effectiveness of the technology as set forth in the systematic assessment conducted under RCW  <a href='http://app.leg.wa.gov/RCW/default.aspx?cite=70.14.100'>70.14.100</a>(4);</div><div style=\"text-indent:0.5in;\">(b) Shall provide an opportunity for public comment; and</div><div style=\"text-indent:0.5in;\">(c) May establish ad hoc temporary advisory groups if specialized expertise is needed to review a particular health technology or group of health technologies, or to seek input from enrollees or clients of state purchased health care programs. Advisory group members are immune from civil liability for any official act performed in good faith as a member of the group. As a condition of appointment, each person shall agree to the terms and conditions imposed by the administrator regarding conflicts of interest.</div><div style=\"text-indent:0.5in;\">(3) Determinations of the committee under subsection (1) of this section shall be consistent with decisions made under the federal medicare program and in expert treatment guidelines, including those from specialty physician organizations and patient advocacy organizations, unless the committee concludes, based on its review of the systematic assessment, that substantial evidence regarding the safety, efficacy, and cost-effectiveness of the technology supports a contrary determination.</div><div style=\"text-indent:0.5in;\"><span style=\"text-decoration:underline;\">(4) The health care authority shall publish receipt of submissions for new technology assessment and rereview assessments on the authority's website within 30 days of receipt. The committee shall review, complete its determination, and communicate its decision for a new technology assessment or rereview assessment to the submitting party within 180 days of the initial date of submission. In the case of an adverse determination, the committee shall provide the submitting party with a written substantive explanation of the rationale for the adverse determination within 180 days of the initial date of submission.</span><!-- field: --></div><!-- field: --><div style=\"margin-top:0.1in;font-weight:bold;text-align:center;\">--- END ---</div></body></html>",
      "summary": "<h3>Purpose</h3>\n<p>The edits made to Substitute House Bill 1076 aim to clarify and enhance the processes regarding the health technology assessment program in Washington State. Key changes include the introduction of clearer timelines for submission and assessment, adjustments to review procedures, and updates on communication timelines regarding technology evaluations. These modifications are intended to streamline operations, improve transparency, and ensure that health technologies undergo rigorous and timely evaluation processes.</p>\n<h3>Key Changes</h3>\n<h4>Title and Identification</h4>\n<ul>\n<li>The original title has been changed from \"HOUSE BILL 1076\" to \"SUBSTITUTE HOUSE BILL 1076.\"</li>\n<li>The bill identification number has changed from \"H-0077.1\" to \"H-1115.1.\"</li>\n</ul>\n<h4>Sponsorship</h4>\n<ul>\n<li>The bill is now sponsored by the \"House Health Care &amp; Wellness\" committee, and the specific representatives' names have been updated to reflect this change.</li>\n</ul>\n<h4>Timeline Adjustments</h4>\n<ul>\n<li>The bill's read date has been updated from \"01/13/25\" to \"02/04/25.\"</li>\n<li>The timeline for the health care authority to publish submissions for new technology assessments and rereviews was changed from \"within seven days\" to \"within 30 days.\"</li>\n</ul>\n<h4>Review Process Changes</h4>\n<ul>\n<li>Adjustments were made in the wording to streamline the evidence review process, specifically regarding the consideration of new evidence for rereview determinations.</li>\n<li>The edited version provides comprehensive instructions for the health technology assessment committee to include evidence from various sources in their decision-making, ensuring a broader context is considered.</li>\n</ul>\n<h4>Public Engagement</h4>\n<ul>\n<li>A clause was retained that emphasizes the opportunity for public comment during the assessment process, supporting community involvement in health technology evaluations.</li>\n</ul>\n<p>These changes collectively enhance the functionality of the health technology assessment program, leading to a more rigorous and responsive evaluation process for health technologies in Washington State.</p>"
    }
  },
  "reports": {},
  "amendments": {}
}